the sun malaysia ipaper logo 150x150
Friday, July 3, 2026
27.5 C
Kuala Lumpur
the sun malaysia ipaper logo 150x150

Health Ministry aims for zero leprosy cases by 2030

KOTA KINABALU: The Ministry of Health (MOH) aims for zero new local leprosy cases by 2030.

Minister Datuk Seri Dr Dzulkefly Ahmad said the cumulative leprosy cases until the 18th epidemiological week as of May 4 were at 66 nationwide, including 24 cases in Sabah.

“The targeted efforts to detect and treat leprosy cases early in the field need to be intensified as a step towards achieving the target of zero new local leprosy cases,“ he said when launching the national-level World Malaria, Tuberculosis, and Leprosy Day at Universiti Malaysia Sabah (UMS) here today.

Dzulkefly said the ministry also provided the single-dose rifampicin as a prophylaxis to leprosy contacts and at-risk communities to prevent the spread of leprosy.

For tuberculosis, he said a total of 8,856 cases were recorded during the same period, including 1,944 cases in Sabah.

Dzulkefly said the disease can be cured by adhering to the prescribed treatment schedule with daily intake of anti-tuberculosis drugs for at least six months.

“Misunderstandings about tuberculosis, such as it being caused by ‘santau’ (black magic), need to be corrected,“ he said, adding that untreated tuberculosis can lead to death.

During the same period, he said a total of 120 cases of human malaria infection and 683 cases of zoonotic malaria infection were recorded nationwide, with five cases of human malaria infection and 404 cases of zoonotic infection in Sabah.

STAY AHEAD OF THE CURVE

Join our community for instant updates and exclusive content.

Join Telegram Channel

Related


spot_img

Latest News

Addressing medical inflation

Consumers are struggling as medical insurance premiums surge, with over 340,000 dropping coverage amid calls for price regulation and stronger public healthcare

Bora Pharmaceuticals Completes Acquisition of MacroGenics’ Rockville Manufacturing Operations

TAIPEI, TAIWAN - Media OutReach Newswire - 2 July 2026 - Bora Pharmaceuticals Co., Ltd. ("Bora" or "Bora Group"; TWSE: 6472; OTCQX: BORAY) today announced the completion of its acquisition of the GMP manufacturing operations of MacroGenics, Inc. (NASDAQ: MGNX) including its biologics drug substance facility in Rockville, Maryland and an associated warehousing center in Frederick, Maryland, for total consideration of US $122.5 million through its wholly owned subsidiary Bora Biologics USA, LLC.. Upon closing, Bora signed a long-term CDMO Service Agreement with MacroGenics.

Most Viewed

spot_img
WC26

World Cup 2026

Updates, Fixtures, Results & Standings